Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lance Leopold, MD
Ascenta Therapeutics, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- Hematology Oncology Associates
Phoenix, Arizona, United States
- Rocky Mountain Cancer Center-Aurora
Aurora, Colorado, United States
- Florida Cancer Institute
Hudson, Florida, United States
- Florida Cancer Institute
New Port Richey, Florida, United States
- Cancer Care & Hematology Specialists of Chicagoland
Arlington Heights, Illinois, United States
- Central Indiana Cancer Centers
Fishers, Indiana, United States
- University of Michigan Cancer Center
Ann Arbor, Michigan, United States
- Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States
- Missouri Cancer Associates
Columbia, Missouri, United States
- Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States
- Hematology/oncology Associates
Albuquerque, New Mexico, United States
- New York Oncology Hematology, P.C.
Albany, New York, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Northwest Cancer Specialists
Portland, Oregon, United States
- the Jones Clinic
Germantown, Tennessee, United States
- Texas Oncology, P.A.
Bedford, Texas, United States
- Texas Cancer Center at Medical City
Dallas, Texas, United States
- Texas Oncology, P.A.
Fort Worth, Texas, United States
- Allison Cancer Center
Midland, Texas, United States
- Hoast - New Braunfels
New Braunfels, Texas, United States
- West Texas Cancer Center
Odessa, Texas, United States
- Hematology Oncology Physicians of Texas
Richardson, Texas, United States
- Tyler Cancer Center
Tyler, Texas, United States
- Virginia Oncology Associates
Chesapeake, Virginia, United States
- Oncology and Hematology Associates of Sw Virginia, Inc.
Salem, Virginia, United States
- Cancer Care Northwest
Spokane, Washington, United States
- St. Mary'S Medical Center
Huntington, West Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2006
- Primary completion
- 30 Nov 2008
- Completion
- 30 Nov 2008
- Last update posted
- 27 Aug 2010
- Registered enrollment
- 23
- Registry id
- NCT00440388
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.